
GLP-1 drugs are remarkably effective at addressing obesity, cardiovascular, and metabolic conditions, but investigators continue to search for solutions that address the root cause of these disorders.
Harith Rajagopalan, MD, PhD, is cofounder and CEO of Fractyl Health, having started the company while serving as an entrepreneur-in-residence at General Catalyst Partners. Prior to founding Fractyl Health, Harith was an academic cardiologist and physician-scientist. He received his BS in chemistry from Stanford University and went on to obtain MD and PhD degrees from Johns Hopkins School of Medicine. At Johns Hopkins, Harith did groundbreaking and award-winning research on intestinal cancers that was published in top medical journals including Nature and Science.
259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512
© 2025 MJH Life Sciences®
All rights reserved.